

# Maher K Gandhi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7660154/publications.pdf>

Version: 2024-02-01

139  
papers

5,652  
citations

76326

40  
h-index

82547

72  
g-index

141  
all docs

141  
docs citations

141  
times ranked

7982  
citing authors

#	ARTICLE	IF	CITATIONS
1	Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma. <i>Haematologica</i> , 2022, 107, 690-701.	3.5	43
2	Neoantigens – the next frontier in precision immunotherapy for B-cell lymphoproliferative disorders. <i>Blood Reviews</i> , 2022, 56, 100969.	5.7	2
3	Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience. <i>British Journal of Haematology</i> , 2021, 192, 1049-1053.	2.5	31
4	EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity. <i>Blood</i> , 2021, 137, 1468-1477.	1.4	59
5	Targeted Treatment of Follicular Lymphoma. <i>Journal of Personalized Medicine</i> , 2021, 11, 152.	2.5	3
6	Immunity reloaded: Deconstruction of the PD-1 axis in B cell lymphomas. <i>Blood Reviews</i> , 2021, 50, 100832.	5.7	5
7	Discordant solutions to discordant problems. <i>Blood</i> , 2021, 137, 2857-2858.	1.4	0
8	Successful treatment of Epstein–Barr virus–associated primary central nervous system lymphoma due to post-transplantation lymphoproliferative disorder, with ibrutinib and third-party Epstein–Barr virus–specific T cells. <i>American Journal of Transplantation</i> , 2021, 21, 3465-3471.	4.7	13
9	Intratumoral T cells have a differential impact on FDG-PET parameters in follicular lymphoma. <i>Blood Advances</i> , 2021, 5, 2644-2649.	5.2	7
10	A cost-effectiveness analysis of front-line treatment strategies in early-stage follicular lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 3484-3492.	1.3	0
11	Characterisation of immune checkpoints in Richter syndrome identifies LAG3 as a potential therapeutic target. <i>British Journal of Haematology</i> , 2021, 195, 113-118.	2.5	8
12	Host Genetic Mutations and Expression Analyses in PTLD. , 2021, , 39-50.		0
13	Intratumoral T cell repertoire is predictive of interim PET scan results in patients with diffuse large B cell lymphoma treated with rituximab/cyclophosphamide/doxorubicin/prednisolone/vincristine (R-CHOP) chemoimmunotherapy. <i>Clinical and Translational Immunology</i> . 2021, 10, e1351.	3.8	1
14	The NLPHL Tumor Microenvironment Is Markedly Enriched in the Tigit and PD-1 Signalling Axes Compared to Classical Hodgkin Lymphoma. <i>Blood</i> , 2021, 138, 3513-3513.	1.4	0
15	Reply to M. Sorigue. <i>Journal of Clinical Oncology</i> , 2020, 38, 648-649.	1.6	1
16	<sc>Risk-adapted</sc> therapy in follicular lymphoma: Is it time to <sc>–FLEX</sc>?. <i>American Journal of Hematology</i> , 2020, 95, 1454-1456.	4.1	1
17	Genetic aberrations of NLRC5 are associated with downregulated MHC–antigen presentation and impaired T cell immunity in follicular lymphoma. <i>EJHaem</i> , 2020, 1, 517-526.	1.0	2
18	DA-EPOCH-R in Burkitt Lymphoma: Is It Enough for High-Risk Disease?. <i>Journal of Clinical Oncology</i> , 2020, 38, 3722-3723.	1.6	1

#	ARTICLE	IF	CITATIONS
19	Increased lipid metabolism impairs NK cell function and mediates adaptation to the lymphoma environment. <i>Blood</i> , 2020, 136, 3004-3017.	1.4	71
20	Cathepsin S Alterations Induce a Tumor-Promoting Immune Microenvironment in Follicular Lymphoma. <i>Cell Reports</i> , 2020, 31, 107522.	6.4	50
21	Targeting an adenosine-mediated $\alpha$ -ketone <sup>TM</sup> eat me signal $\alpha$ ugments anti-lymphoma immunity by anti-CD20 monoclonal antibody. <i>Leukemia</i> , 2020, 34, 2708-2721.	7.2	27
22	LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphoma. <i>Blood Advances</i> , 2020, 4, 1367-1377.	5.2	66
23	Neoantigens Are Typically Associated with Intact HLA Class I Presentation in Early-Stage Follicular Lymphoma. <i>Blood</i> , 2020, 136, 37-38.	1.4	1
24	A Cost-Effectiveness Analysis of Front-Line Treatment Strategies in Early Stage Follicular Lymphoma. <i>Blood</i> , 2020, 136, 54-55.	1.4	1
25	Progression of Disease Within 24 Months in Follicular Lymphoma Is Associated With Reduced Intratumoral Immune Infiltration. <i>Journal of Clinical Oncology</i> , 2019, 37, 3300-3309.	1.6	83
26	The tumour microenvironment is immunotolerogenic and a principal determinant of patient outcome in EBV $\alpha$ positive diffuse large B $\alpha$ cell lymphoma. <i>European Journal of Haematology</i> , 2019, 103, 200-207.	2.2	42
27	Biology and therapy of primary mediastinal B $\alpha$ cell lymphoma: current status and future directions. <i>British Journal of Haematology</i> , 2019, 185, 25-41.	2.5	51
28	EBV microRNA-BHRF1-2-5p targets the 3 $\alpha$ UTR of immune checkpoint ligands PD-L1 and PD-L2. <i>Blood</i> , 2019, 134, 2261-2270.	1.4	44
29	Human peripheral blood DNAM-1neg NK cells are a terminally differentiated subset with limited effector functions. <i>Blood Advances</i> , 2019, 3, 1681-1694.	5.2	24
30	COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study. <i>Blood Advances</i> , 2019, 3, 2013-2021.	5.2	40
31	Outcomes of stage I/II follicular lymphoma in the PET era: an international study from the Australian Lymphoma Alliance. <i>Blood Advances</i> , 2019, 3, 2804-2811.	5.2	15
32	Simple, rapid and inexpensive typing of common HLA class I alleles for immunological studies. <i>Journal of Immunological Methods</i> , 2019, 465, 72-76.	1.4	6
33	Intra-Tumoral CD8+ T-Cells in Follicular Lymphoma Contain Large Clonal Expansions That Are Amenable to Dual-Checkpoint Blockade. <i>Blood</i> , 2019, 134, 2793-2793.	1.4	2
34	A Complicated Neighborhood: Insights into the Hodgkin Lymphoma Microenvironment. <i>Blood</i> , 2019, 134, SCI-8-SCI-8.	1.4	0
35	Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL. <i>Blood</i> , 2018, 131, 1809-1819.	1.4	231
36	B cell lymphoma progression promotes the accumulation of circulating Ly6Clo monocytes with immunosuppressive activity. <i>Oncolmmunology</i> , 2018, 7, e1393599.	4.6	17

#	ARTICLE	IF	CITATIONS
37	Epigenetically reprogrammed methylation landscape drives the DNA self-assembly and serves as a universal cancer biomarker. <i>Nature Communications</i> , 2018, 9, 4915.	12.8	135
38	Elevated LAG-3 Expression in the Tumor Microenvironment of Patients with DLBCL Is Associated with a Non-GCB Phenotype and Poor Prognosis. <i>Blood</i> , 2018, 132, 1576-1576.	1.4	1
39	Outcomes of Stage I and II Follicular Lymphoma in the Era of 18F-FDG PET-CT Staging: An International Collaborative Study from the Australian Lymphoma Alliance. <i>Blood</i> , 2018, 132, 4148-4148.	1.4	1
40	A high LDH to absolute lymphocyte count ratio in patients with DLBCL predicts for a poor intratumoral immune response and inferior survival. <i>Oncotarget</i> , 2018, 9, 23620-23627.	1.8	19
41	Circulating cell-free miR-494 and miR-21 are disease response biomarkers associated with interim-positron emission tomography response in patients with diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2018, 9, 34644-34657.	1.8	14
42	The Tumor Microenvironment of Nodular Lymphocyte Predominant Hodgkin Lymphoma Is a Unique Immunobiological Entity Distinct from Classical Hodgkin Lymphoma. <i>Blood</i> , 2018, 132, 4123-4123.	1.4	4
43	Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14. <i>Haematologica</i> , 2017, 102, 356-363.	3.5	53
44	The T-cell Receptor Repertoire Influences the Tumor Microenvironment and Is Associated with Survival in Aggressive B-cell Lymphoma. <i>Clinical Cancer Research</i> , 2017, 23, 1820-1828.	7.0	65
45	The Tumor Microenvironment Is Independently Prognostic of Conventional and Clinicogenetic Risk Models in Follicular Lymphoma. <i>Blood</i> , 2017, 130, 728-728.	1.4	2
46	The T-Cell Receptor Repertoire Predicts Interim-PET in Patients with DLBCL Treated with R-CHOP: An Observational Study from a Prospective Clinical Trial. <i>Blood</i> , 2017, 130, 825-825.	1.4	0
47	Dielectrophoretic Microfluidic Chip Enables Single-Cell Measurements for Multidrug Resistance in Heterogeneous Acute Myeloid Leukemia Patient Samples. <i>Analytical Chemistry</i> , 2016, 88, 5680-5688.	6.5	35
48	Recent treatment advances in Hodgkin lymphoma: a concise review. <i>Internal Medicine Journal</i> , 2016, 46, 1364-1369.	0.8	6
49	The impact of HLA class I and EBV latency-II antigen-specific CD8+ T cells on the pathogenesis of EBV+ Hodgkin lymphoma. <i>Clinical and Experimental Immunology</i> , 2016, 183, 206-220.	2.6	38
50	Whole blood EBV-DNA: A surrogate for immune dysfunction in aggressive lymphoma?. <i>Leukemia and Lymphoma</i> , 2016, 57, 507-508.	1.3	4
51	A Novel Anti-Lymphoma Immune Evasion Mediated By the Interaction Between PD-1 Enriched NK-Cells and CD163+PD-L1+PD-L2+ Tumor Associated Macrophages, That Is More Prominent in Hodgkin Lymphoma Than Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 918-918.	1.4	2
52	HLA class I associations with EBV+ post-transplant lymphoproliferative disorder. <i>Transplant Immunology</i> , 2015, 32, 126-130.	1.2	10
53	Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. <i>Blood</i> , 2015, 125, 3679-3687.	1.4	270
54	Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study. <i>Lancet Haematology</i> , 2015, 2, e445-e455.	4.6	74

#	ARTICLE	IF	CITATIONS
55	Cessation of immunosuppression during chemotherapy for post-transplant lymphoproliferative disorders in renal transplant patients. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1774-1779.	0.7	13
56	Deregulated JAK/STAT signalling in lymphomagenesis, and its implications for the development of new targeted therapies. <i>Blood Reviews</i> , 2015, 29, 405-415.	5.7	38
57	Early Treatment Intensification with R-ICE Chemotherapy Followed By Autologous Stem Cell Transplantation (ASCT) Using Zevalin-BEAM for Patients with Poor Risk Diffuse Large B-Cell Lymphoma (DLBCL) As Identified By Interim PET/CT Scan Performed after Four Cycles of R-CHOP-14: A Multicenter Phase II Study of the Australasian Leukaemia Lymphoma Study Group (ALLG). <i>Blood</i> , 2015, 126, 815-815.	1.4	7
58	Serum CD163 and TARC as Circulating Biomarkers in Hodgkin Lymphoma. <i>Biomarkers in Disease</i> , 2015, , 955-978.	0.1	0
59	The T Cell Receptor (TCR) Repertoire Is a Key Determinant of the Tumour Microenvironment (TME) in Diffuse Large B Cell Lymphoma (DLBCL). <i>Blood</i> , 2015, 126, 3893-3893.	1.4	0
60	Fc $\gamma$ 3-Receptor IIIA Polymorphism p.158F Has No Negative Predictive Impact on Rituximab Therapy with and without Sequential Chemotherapy in CD20-Positive Posttransplant Lymphoproliferative Disorder. <i>Journal of Immunology Research</i> , 2014, 2014, 1-6.	2.2	3
61	A Comprehensive Analysis of the Cellular and EBV-Specific MicroRNAome in Primary CNS PTLD Identifies Different Patterns Among EBV-Associated Tumors. <i>American Journal of Transplantation</i> , 2014, 14, 2577-2587.	4.7	50
62	The presence of KIR2DS5 confers protection against adult immune thrombocytopenia. <i>Tissue Antigens</i> , 2014, 83, 154-160.	1.0	13
63	Plasma MicroRNA Are Disease Response Biomarkers in Classical Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2014, 20, 253-264.	7.0	117
64	A new frontier in haematology – combining pharmacokinetic with pharmacodynamic factors to improve choice and dose of drug. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 274-281.	2.4	8
65	A multicentre, single-arm, open-label study evaluating the safety and efficacy of fixed dose rituximab in patients with refractory, relapsed or chronic idiopathic thrombocytopenic purpura (R&gt;ITP&gt;1000 study). <i>British Journal of Haematology</i> , 2014, 167, 243-251.	2.5	27
66	In silico analyses reveal common cellular pathways affected by loss of heterozygosity (LOH) events in the lymphomagenesis of Non-Hodgkin's lymphoma (NHL). <i>BMC Genomics</i> , 2014, 15, 390.	2.8	8
67	Circulating Biomarkers in Hodgkin Lymphoma. , 2014, , 1-19.		0
68	Noninvasive monitoring of cellular versus acellular tumor DNA from immunoglobulin genes for DLBCL. <i>Journal of Clinical Oncology</i> , 2014, 32, 8504-8504.	1.6	0
69	Net antitumoral immunity and the predictive power of conventional prognosticators in diffuse large B-cell lymphoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 8542-8542.	1.6	0
70	Validation of Elevated Blood Soluble PD-L1 As an Independent Prognostic Marker in Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2014, 124, 2998-2998.	1.4	2
71	Primary CNS Posttransplant Lymphoproliferative Disease (PTLD): An International Report of 84 Cases in the Modern Era. <i>American Journal of Transplantation</i> , 2013, 13, 1512-1522.	4.7	150
72	CD4 <sup>+</sup> Tumor infiltrating lymphocytes are prognostic and independent of R&gt;PI in patients with DLBCL receiving R&gt;CHOP chemotherapy. <i>American Journal of Hematology</i> , 2013, 88, 273-276.	4.1	71

#	ARTICLE	IF	CITATIONS
73	High-resolution loss of heterozygosity screening implicates <i>PTPRJ</i> as a potential tumor suppressor gene that affects susceptibility to non-Hodgkin's lymphoma. <i>Genes Chromosomes and Cancer</i> , 2013, 52, 467-479.	2.8	19
74	Serum CD163 and TARC as Disease Response Biomarkers in Classical Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2013, 19, 731-742.	7.0	91
75	Abstract B38: FOXP1 truncated isoforms differentially regulate target genes in diffuse large B cell lymphoma. , 2013, , .		0
76	HLA-Class I Alleles Impact Susceptibility To EBV+ Classical Hodgkin Lymphoma By Altering EBV Latent Antigen-Specific CD8+ T-Cell Immune Hierarchies. <i>Blood</i> , 2013, 122, 630-630.	1.4	0
77	Immunosuppression (IST) Can Be Safely Ceased During Chemotherapy For Post-Transplant Lymphoproliferative Disorders (PTLD) In Renal Transplant Patients. <i>Blood</i> , 2013, 122, 1780-1780.	1.4	0
78	The Epstein-Barr virus microRNA BART11-5p targets the early B-cell transcription factor EBF1. <i>American Journal of Blood Research</i> , 2013, 3, 210-24.	0.6	19
79	The KIR2DS2/DL2 genotype is associated with adult persistent/chronic and relapsed immune thrombocytopenia independently of FCGR3a-158 polymorphisms. <i>Blood Coagulation and Fibrinolysis</i> , 2012, 23, 45-50.	1.0	16
80	Back to basics: the complete blood cell count adds to the ability of immunohistochemistry in diffuse large B-cell lymphoma prognosis. <i>Leukemia and Lymphoma</i> , 2012, 53, 2097-2098.	1.3	1
81	Homozygous <i>FCGR3A</i> $\Delta 158V$ alleles predispose to late onset neutropenia after <i>CHOP-R</i> for diffuse large <i>B</i> -cell lymphoma. <i>Internal Medicine Journal</i> , 2012, 42, 1113-1119.	0.8	23
82	Expression profiling of Epstein-Barr virus-encoded microRNAs from paraffin-embedded formalin-fixed primary Epstein-Barr virus-positive B-cell lymphoma samples. <i>Journal of Virological Methods</i> , 2012, 184, 46-54.	2.1	25
83	Tumor-specific but not nonspecific cell-free circulating DNA can be used to monitor disease response in lymphoma. <i>American Journal of Hematology</i> , 2012, 87, 258-265.	4.1	30
84	EBNA3B-deficient EBV promotes B cell lymphomagenesis in humanized mice and is found in human tumors. <i>Journal of Clinical Investigation</i> , 2012, 122, 1487-1502.	8.2	132
85	Serum CD163 and TARC in Combination As Disease Response Biomarkers in Classical Hodgkin Lymphoma. <i>Blood</i> , 2012, 120, 49-49.	1.4	0
86	Identification of FOXP1 Transcriptional Targets in Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2012, 120, 5119-5119.	1.4	0
87	Epstein-Barr Virus-Related Post-Transplant Lymphoproliferative Disorders: Pathogenetic Insights for Targeted Therapy. <i>American Journal of Transplantation</i> , 2011, 11, 888-895.	4.7	117
88	Integrative genomic profiling reveals conserved genetic mechanisms for tumorigenesis in common entities of non-Hodgkin's lymphoma. <i>Genes Chromosomes and Cancer</i> , 2011, 50, 313-326.	2.8	45
89	Broad-spectrum immunosuppression by classless monocytes in non-Hodgkin's lymphoma. <i>Immunotherapy</i> , 2011, 3, 723-726.	2.0	1
90	Optimizing tumor-targeting chimeric antigen receptor T cells in B-cell lymphoma patients. <i>Immunotherapy</i> , 2011, 3, 1441-1443.	2.0	3

#	ARTICLE	IF	CITATIONS
91	A novel immunodeficiency disorder characterized by genetic amplification of interleukin 25. <i>Genes and Immunity</i> , 2011, 12, 663-666.	4.1	8
92	Tissue Microarray in DLBCL Patients receiving R-CHOP Chemo-Immunotherapy Shows Survival Benefit for Coexpression of LMO2/BCL6. <i>Blood</i> , 2011, 118, 1585-1585.	1.4	1
93	Monocytes Are Associated with Impaired T-Cell Immunity and Residual Interim-PET/CT Avidity After 4 Cycles of CHOP-R In Patients with High-Risk DLBCL. <i>Blood</i> , 2011, 118, 3673-3673.	1.4	1
94	Loss of Heterozygosity (LOH) of PTPRJ in Non-Hodgkin's Lymphoma (NHL). <i>Blood</i> , 2011, 118, 5231-5231.	1.4	0
95	A Multi-Centre, Single-Arm, Open-Label Study Evaluating the Safety and Efficacy of Fixed Dose Rituximab in Patients with Refractory, Relapsing or Chronic Idiopathic Thrombocytopenic Purpura (R-ITP1000 Study) and Exploring Rituximab Response with the FcGammaR3A Polymorphisms. <i>Blood</i> , 2011, 118, 1157-1157.	1.4	0
96	Molecular mechanisms influencing NK cell development: implications for NK cell malignancies. <i>American Journal of Blood Research</i> , 2011, 1, 34-45.	0.6	3
97	Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly expresses EBNA3A with conserved CD8 T-cell epitopes. <i>American Journal of Blood Research</i> , 2011, 1, 146-59.	0.6	19
98	Expansion of EBNA1-specific effector T cells in posttransplantation lymphoproliferative disorders. <i>Blood</i> , 2010, 116, 2245-2252.	1.4	65
99	Sodium valproate in combination with ganciclovir induces lysis of EBV-infected lymphoma cells without impairing EBV-specific T cell immunity. <i>International Journal of Laboratory Hematology</i> , 2010, 32, e169-74.	1.3	26
100	Fulminant Infectious Mononucleosis and Recurrent Epstein-Barr Virus Reactivation in an Adolescent. <i>Clinical Infectious Diseases</i> , 2010, 50, e34-e37.	5.8	4
101	Can a blood test monitor lymphoma?. <i>Leukemia and Lymphoma</i> , 2010, 51, 957-959.	1.3	3
102	What changes are needed to the current direction and interpretation of clinical cancer research to meet the needs of the 21st century?. <i>Medical Journal of Australia</i> , 2009, 190, 461-461.	1.7	1
103	The role of Epstein-Barr virus in Richter syndrome. <i>British Journal of Haematology</i> , 2009, 144, 613-613.	2.5	1
104	High levels of BACH2 associated with lower levels of BCL2 transcript abundance in t(14;18)(q21;q34) translocation positive non-Hodgkin's lymphoma. <i>Leukemia Research</i> , 2009, 33, 731-734.	0.8	10
105	Relative abundance of full-length and truncated FOXP1 isoforms is associated with differential NF- $\kappa$ B activity in Follicular Lymphoma. <i>Leukemia Research</i> , 2009, 33, 1699-1702.	0.8	25
106	Epstein-Barr virus DNA as a biomarker for Epstein-Barr virus-positive lymphomas: are we there yet?. <i>Leukemia and Lymphoma</i> , 2009, 50, 684-686.	1.3	4
107	Selective accumulation of virus-specific CD8+ T cells within the peripheral blood stem cell compartment. <i>Blood</i> , 2009, 114, 2001-2003.	1.4	21
108	EBV MicroRNA Expression in Virus Driven B-Cell Differentiation and Lymphomagenesis. <i>Blood</i> , 2009, 114, 93-93.	1.4	0

#	ARTICLE	IF	CITATIONS
109	Immunodeficiency-associated lymphomas. <i>Blood Reviews</i> , 2008, 22, 261-281.	5.7	149
110	A new prognosticator for post-transplant lymphoproliferative disorders after renal transplantation. <i>British Journal of Haematology</i> , 2008, 141, 904-907.	2.5	29
111	A case of transfusion-acquired hepatitis C. <i>International Journal of Laboratory Hematology</i> , 2008, 15, 141-144.	0.2	1
112	Inducing remission in drug resistant acute myeloid leukaemia with cyclosporin A. <i>International Journal of Laboratory Hematology</i> , 2008, 15, 219-221.	0.2	0
113	Methotrexate-associated mantle-cell lymphoma in an elderly man with myasthenia gravis. <i>Nature Clinical Practice Oncology</i> , 2008, 5, 234-238.	4.3	10
114	Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. <i>Blood</i> , 2007, 110, 1123-1131.	1.4	584
115	Galectin-1 mediated suppression of Epstein-Barr virus-specific T-cell immunity in classic Hodgkin lymphoma. <i>Blood</i> , 2007, 110, 1326-1329.	1.4	145
116	The use of T-cell directed cellular therapies in Australia. <i>Cytotherapy</i> , 2007, 9, 222-224.	0.7	2
117	Epstein-Barr virus T-cell immunity despite rituximab. <i>British Journal of Haematology</i> , 2007, 136, 628-632.	2.5	14
118	Immunity, Homing and Efficacy of Allogeneic Adoptive Immunotherapy for Posttransplant Lymphoproliferative Disorders. <i>American Journal of Transplantation</i> , 2007, 7, 1293-1299.	4.7	58
119	Correlation of T-cell immune response with spontaneous resolution and subsequent relapse of Hodgkin's lymphoma. <i>Leukemia and Lymphoma</i> , 2006, 47, 871-876.	1.3	8
120	Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T-cell function in Hodgkin lymphoma patients. <i>Blood</i> , 2006, 108, 2280-2289.	1.4	215
121	Functional Reversion of Antigen-Specific CD8+ T Cells from Patients with Hodgkin Lymphoma following In Vitro Stimulation with Recombinant Polyepitope. <i>Journal of Immunology</i> , 2006, 177, 4897-4906.	0.8	63
122	Plasma Epstein-Barr Virus (EBV) DNA Is a Biomarker for EBV-Positive Hodgkin's Lymphoma. <i>Clinical Cancer Research</i> , 2006, 12, 460-464.	7.0	129
123	Epstein-Barr virus and advanced chronic lymphocytic leukemia: innocent until proven guilty?. <i>Leukemia and Lymphoma</i> , 2006, 47, 779-780.	1.3	4
124	Epstein-Barr virus-associated lymphomas. <i>Expert Review of Anti-Infective Therapy</i> , 2006, 4, 77-89.	4.4	34
125	Regulation of clinical research. <i>Clinical Medicine</i> , 2005, 5, 299.1-299.	1.9	0
126	Viruses and lymphoma. <i>Pathology</i> , 2005, 37, 420-433.	0.6	14



#	ARTICLE	IF	CITATIONS
127	Follicular lymphoma: time for a re-think?. <i>Blood Reviews</i> , 2005, 19, 165-178.	5.7	36
128	Technology Insight: applications of emerging immunotherapeutic strategies for Epstein-Barr virus-associated malignancies. <i>Nature Clinical Practice Oncology</i> , 2005, 2, 138-149.	4.3	61
129	Epstein-Barr virus-associated Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 2004, 125, 267-281.	2.5	123
130	Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. <i>Lancet Infectious Diseases</i> , 2004, 4, 725-738.	9.1	486
131	Human cytomegalovirus-specific immunity following haemopoietic stem cell transplantation. <i>Blood Reviews</i> , 2003, 17, 259-264.	5.7	28
132	Significant and persistent loss of bone mineral density in the femoral neck after haematopoietic stem cell transplantation: long-term follow-up of a prospective study. <i>British Journal of Haematology</i> , 2003, 121, 462-468.	2.5	68
133	Late diversification in the clonal composition of human cytomegalovirus-specific CD8+ T cells following allogeneic hemopoietic stem cell transplantation. <i>Blood</i> , 2003, 102, 3427-3438.	1.4	59
134	Identification of Naive or Antigen-Experienced Human CD8+ T Cells by Expression of Costimulation and Chemokine Receptors: Analysis of the Human Cytomegalovirus-Specific CD8+ T Cell Response. <i>Journal of Immunology</i> , 2002, 168, 5455-5464.	0.8	189
135	Antibody responses to vaccinations given within the first two years after transplant are similar between autologous peripheral blood stem cell and bone marrow transplant recipients. <i>Bone Marrow Transplantation</i> , 2001, 28, 775-781.	2.4	78
136	A comparison of molecular and enzyme-based assays for the detection of thiopurine methyltransferase mutations. <i>British Journal of Haematology</i> , 2000, 110, 599-604.	2.5	40
137	The minimum CD34 threshold depends on prior chemotherapy in autologous peripheral blood stem cell recipients. <i>Bone Marrow Transplantation</i> , 1999, 23, 9-13.	2.4	58
138	A comparison of CD34+ cell selected and unselected autologous peripheral blood stem cell transplantation for multiple myeloma: a case controlled analysis. <i>Bone Marrow Transplantation</i> , 1999, 24, 369-375.	2.4	19
139	A trend towards an increased incidence of chronic graft-versus-host disease following allogeneic peripheral blood progenitor cell transplantation: a case controlled study. <i>Bone Marrow Transplantation</i> , 1998, 22, 273-276.	2.4	43